

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

TRAIL

Human, Recombinant Expressed in NS0 mouse myeloma cells

Product Number **T 5694** Storage Temperature - 20 °C

Synonyms: TNF-Related Apoptosis-Inducing Ligand, TNFSF10, Apo-2 ligand, Apo-2L

Product Description

The extracellular domain of human TRAIL (Thr⁹⁵– Gly²⁸¹)¹ having a histidine tag at the amino terminus was expressed in a mouse myeloma cell line, NS0.

TRAIL is a type II transmembrane protein with a carboxy-terminal extracellular domain that exhibits homology to other TNF family members. In the new TNF family nomenclature, TRAIL is referred to as TNFSF10. Human TRAIL is a protein composed of 281 amino acid residues with an amino-terminal intracellular domain of 17 residues and a predicted internal hydrophobic domain between residues 18 and 38. The extracellular carboxy-terminal domain contains the receptor-binding domain and a potential N-linked glycosylation site at amino acid residue 109.

Human TRAIL shares about 65% amino acid sequence homology with mouse TRAIL and is active on mouse cells. Recombinant human TRAIL can be injected into mice without toxic side effects. Both membrane-bound and soluble TRAIL have been shown to induce the rapid apoptosis of many transformed cell lines but not of normal cells.^{2,3}

Like most TNF family members, bioactive TRAIL is a non-disulfide-linked homotrimer. Constitutive expression of TRAIL transcripts occurs in a variety of human tissues. TRAIL is a ligand for two death domain-containing receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5) that transduce the apoptotic signals. These receptors are members of the TNF receptor family that also includes FAS and TNFR. TRAIL also binds to three decoy receptors that antagonize TRAIL-induced apoptosis. An adenovirus protein, RID, has been shown to inhibit TRAIL-induced apoptosis. This apoptosis inducer is thought to be regulated by the transcription factor NF-κB.

Reagent

Recombinant human TRAIL is lyophilized from a 0.2 μ m-filtered solution in phosphate-buffered saline containing 50 μ g bovine serum albumin per 1 μ g TRAIL.

Precautions and Disclaimer

For laboratory use only. Not for drug, household or other uses. Please consult the Material Safety Data Sheet for handling recommendations before working with this material.

Storage/Stability

Lyophilized recombinant human TRAIL is stable for at least 6 months at -20 $^{\circ}$ C. A stock solution containing at least 20 μ g protein per ml can be stored under sterile conditions at 2-8 $^{\circ}$ C for one month and in single-use aliquots for six months at -70 $^{\circ}$ C without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Product Profile

Recombinant human TRAIL may contain up to 10% disulfide-linked homodimers. The monomeric extracellular domain of recombinant human TRAIL has a predicted molecular mass of approximately 21 kDa but migrates as a 24 kDa protein in SDS-PAGE under reducing conditions, perhaps due to glycosylation.

The activity of recombinant human TRAIL is determined by the induction of cytotoxicity in mouse L-929 cells in the presence of the metabolic inhibitor actinomycin D.⁸ The ED₅₀ for this effect is in the range of 4–12 ng/ml.

The purity of recombinant human TRAIL is >97% determined by SDS-PAGE with silver staining

References

1. Wiley, S.R. *et al.*, Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity **3**, 673-682 (1995).

- Pitti, R.M. et al., Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271, 12687-12690 (1996).
- 3. Suliman, A., et al., Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene, **20**, 2122-2133 (2001).
- 4. Golstein, P., Cell death: TRAIL and its receptors. Curr. Biol., **7**, R750–R753 (1997).
- 5. Chaudhary P.M. *et al.*, Death receptor 5, a new member of the TNFR family, and DR4 induce

- FADD-dependent apoptosis and activate the NF-κB pathway. Immunity **7**:821-830 (1997).
- 6. Tollefson, A.E., et al., Inhibition of trail-induced apoptosis and forced internalization of trail receptor 1 by adenovirus proteins. J. Virol., **75**, 8875-8887 (2001).
- 7. Baetu, T.M., et al., Disruption of NF- κ B signaling reveals a novel role for NF- κ B in the regulation of TNF-related apoptosis-inducing ligand expression. J. Immunol., **167**, 3164-3173 (2001).
- 8. Matthews, N., et al. in Lymphokines and Interferons: A Practical Approach, M.J. Clemens, et al., eds., IRL Press, p.221 (1987).

RBR 9/01